Ignite Creation Date:
2025-12-24 @ 10:15 PM
Ignite Modification Date:
2026-03-01 @ 5:17 PM
Study NCT ID:
NCT02362035
Status:
COMPLETED
Last Update Posted:
2025-12-11
First Post:
2015-02-07
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Sponsor:
Acerta Pharma BV
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2015-02-20
Start Date Type:
ACTUAL
Primary Completion Date:
2020-07-14
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-10-27
Completion Date Type:
ACTUAL
First Submit Date:
2015-02-07
First Submit QC Date:
None
Study First Post Date:
2015-02-12
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-07-05
Results First Submit QC Date:
None
Results First Post Date:
2022-05-06
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-25
Last Update Post Date:
2025-12-11
Last Update Post Date Type:
ESTIMATED